Budesonide (controlled ileal release)
Treatment for Crohns Disease
Typical Dosage: 9 mg oral daily for 8 weeks, then taper
Effectiveness
60%
Safety Score
50%
Clinical Trials
30
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
9 mg oral daily for 8 weeks, then taper
Time to Effect
2-4 weeks
Treatment Duration
8-12 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$750
Monitoring:$450
Side Effect Mgmt:$100
Total Annual:$1,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.01
Outcome-Based Costs
Cost per Responder
$2,364
Cost per Remission
$3,250
Budesonide (controlled ileal release) Outcomes
for Crohns Disease
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+55%
Remission Rate
+40%
Common Side Effects
Headache
+15%
Nausea
+8%
Acne
+7%
Adrenal suppression
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov